Skip to content

2013 ESH/ESC Guidelines for the management of arterial hypertension

Giuseppe Mancia, Robert H. Fagard, Krzysztof Narkiewicz, Josep Redón, Alberto Zanchetti, Michael Böhm, Thierry CM Christiaens, Renata Cífková, Guy De Backer, Anna F. Dominiczak, Maurizio Galderisi, Diederick E. Grobbee, Tiny Jaarsma, Paulus F. Kirchhof, Sverre Erik Kjeldsen, Stéphane Laurent, Athanasios John Manolis, Peter M. Nilsson, Luis Miguel Ruilope, Roland Erich Schmieder, Per Anton Sirnes, Peter Sleight, Margus Viigimaa, Bernard Waeber, Faiez M. Zannad

Journal of Hypertension · 2013 · 5,764 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Mancia, G., Fagard, R. H., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T. C., Cífková, R., Backer, G. D., Dominiczak, A. F., Galderisi, M., Grobbee, D. E., Jaarsma, T., Kirchhof, P. F., Kjeldsen, S. E., Laurent, S., Manolis, A. J., Nilsson, P. M., Ruilope, L. M., … Zannad, F. M. (2013). 2013 ESH/ESC guidelines for the management of arterial hypertension. Journal of Hypertension, 31(7), 1281–1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc

In text: (Mancia et al., 2013)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

Table of Contents Introduction Principles New aspects Epidemiological aspects Relationship of blood pressure to cardiovascular and renal damage Definition and classification of hypertension Prevalence of hypertension Hypertension and total cardiovascular risk Assessment of total cardiovascular risk Limitations Summary of recommendations on total cardiovascular risk assessment Diagnostic evaluation Bood pressure measurement Office or clinic blood pressure Out-of-office blood pressure White-coat (or isolated office) hypertension and masked (or isolated ambulatory) hypertension Clinical indications for out-of-office blood pressure Blood pressure during exercise and laboratory stress Central blood pressure Medical history Physical examination Summary of recommendations on blood pressure measurement, history, and physical examination Laboratory investigations Genetics Searching for asymptomatic organ damage Heart Blood vessels Kidney Fundoscopy Brain Clinical value and limitations Summary of recommendations on the search for asymptomatic organ damage, cardiovascular disease, and chronic kidney disease Searching for secondary forms of hypertension Treatment approach Evidence favouring therapeutic reduction of high blood pressure When to initiate antihypertensive drug treatment Recommendations of previous Guidelines Grade 2 and 3 hypertension and high-risk grade 1 hypertension Low-to-moderate risk, grade 1 hypertension Isolated systolic hypertension in youth Grade 1 hypertension in the elderly High normal blood pressure Summary of recommendations on initiation of antihypertensive drug treatment Blood pressure treatment targets Recommendations of previous Guidelines Low-to-moderate risk hypertensive patients Hypertension in the elderly High-risk patients The ‘lower the better’ vs. the J-shaped curve hypothesis Evidence on target blood pressure from organ damage studies Clinic vs. home and ambulatory blood pressure targets Summary of recommendations on blood pressure targets in hypertensive patients Treatment strategies Lifestyle changes Salt restriction Moderation of alcohol consumption Other dietary changes Weight reduction Regular physical exercise Smoking cessation Summary of recommendations on adoption of lifestyle changes Pharmacological therapy Choice of antihypertensive drugs Monotherapy and combination therapy Summary of recommendations on treatment strategies and choice of drugs Treatment strategies in special conditions White-coat hypertension Masked hypertension Summary of recommendations on treatment strategies in white-coat and masked hypertension Elderly Summary of recommendations on antihypertensive treatment strategies in the elderly Young adults Women Oral contraceptives Hormone replacement therapy Pregnancy Long-term cardiovascular consequences in gestational hypertension Summary of recommendations on treatment strategies in hypertensive women Diabetes mellitus Summary of recommendations on treatment strategies in patients with diabetes Metabolic syndrome Summary of recommendations on treatment strategies in hypertensive patients with metabolic syndrome Obstructive sleep apnoea Diabetic and non-diabetic nephropathy Summary of recommendations on therapeutic strategies in hypertensive patients with nephropathy Chronic kidney disease stage 5D Cerebrovascular disease Acute stroke Previous stroke or transient ischaemic attack Cognitive dysfunction and white matter lesions Summary of recommendations on therapeutic strategies in hypertensive patients with cerebrovascular disease Heart disease Coronary heart disease Heart failure Atrial fibrillation Left ventricular hypertrophy Summary of recommendations on therapeutic strategies in hypertensive patients with heart disease Atherosclerosis, arteriosclerosis, and peripheral artery disease Carotid atherosclerosis Increased arterial stiffness Peripheral artery disease Summary of recommendations on therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease Sexual dysfunction Resistant hypertension Carotid baroreceptor stimulation Renal denervation Other invasive approaches Follow-up in resistant hypertension Summary of recommendations on therapeutic strategies in patients with resistant hypertension Malignant hypertension Hypertensive emergencies and urgencies Perioperative management of hypertension Renovascular hypertension Primary aldosteronism Treatment of associated risk factors Lipid-lowering agents Antiplatelet therapy Treatment of hyperglycaemia Summary of recommendations on treatment of risk factors associated with hypertension Follow-up Follow-up of hypertensive patients Follow-up of subjects with high normal blood pressure and white-coat hypertension Elevated blood pressure at control visits Continued search for asymptomatic organ damage Can antihypertensive medications be reduced or stopped? Improvement of blood pressure control in hypertension Hypertension disease management Team approach in disease management Mode of care delivery The role of information and communication technologies 53 Gaps in evidence and need for future trials Appendix 1 Appendix 2 Acknowledgments References 1. INTRODUCTION 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) follow the guidelines jointly issued by the two societies in 2003 and 2007 [1,2]. Publication of a new document 6 years after the previous one was felt to be timely because, over this period, important studies have been conducted and many new results have been published on both the diagnosis and treatment of individuals with an elevated blood pressure (BP), making refinements, modifications and expansion of the previous recommendations necessary. The 2013 ESH/ESC guidelines continue to adhere to some fundamental principles that inspired the 2003 and 2007 guidelines, namely (i) to base recommendations on properly conducted studies identified from an extensive review of the literature, (ii) to consider, as the highest priority, data from randomized, controlled trials (RCTs) and their meta-analyses, but not to disregard—particularly when dealing with diagnostic aspects—the results of observational and other studies of appropriate scientific calibre, and (iii) to grade the level of scientific evidence and the strength of recommendations on major diagnostic and treatment issues as in European guidelines on other diseases, according to ESC recommendations (Tables 1 and 2). While it was not done in the 2003 and 2007 guidelines, providing the recommendation class and the level of evidence is now regarded as important for providing interested readers with a standard approach, by which to compare the state of knowledge across different fields of medicine. was that this on recommendations that on the of the on is not in because, for a of is and recommendations from and both of which be When this guidelines as and the of studies and evidence is in with is to a of and a of recommendations that be and by in their of of European of the in of the 2013 guidelines on hypertension have been by the and on their and of major of of forms be on the ESC and was a which was by and by two one by and by The was over during which the and with one the document was by European by and by be that the recommendations issued by the 2013 ESH/ESC guidelines on hypertension the state of the on as by and in for and the have been by and New aspects of new evidence on diagnostic and therapeutic aspects of the guidelines in many from the previous of the important Epidemiological data on hypertension and control in of the value of home blood pressure and of role for diagnosis and management of to ambulatory blood pressure of the of white-coat hypertension and masked on of cardiovascular risk asymptomatic organ damage and for total risk of the of asymptomatic blood and of the risk of and target in Hypertension in of antihypertensive and drug treatment of high normal for and target systolic blood pressure in both and risk approach to for New therapeutic for target on therapeutic strategies in special recommendations on treatment of hypertension in the treatment of to resistant hypertension and new treatment Increased to New approaches to chronic management of hypertensive Relationship of blood pressure to cardiovascular and renal damage The and and renal been in a of observational studies The in in the 2003 and 2007 ESH/ESC guidelines be as Office an with the of heart failure and peripheral artery disease as as of renal disease is at and in The with from high to of for and for to be a of after the of years and in elderly individuals pressure and been to have a role is by the high risk by patients with an elevated and a normal or systolic hypertension with is by out-of-office as by and The and and is by the of other risk Metabolic risk factors when is high when it is Definition and classification of hypertension The and and renal the and hypertension when on is because, in the and have a both to the diagnostic approach and to the The classification is from the 2003 and 2007 ESH/ESC guidelines Hypertension is as on the evidence from that in patients with and The classification is in and elderly different on in and for data from trials not on classification in and according to their and be in the on the evaluation and treatment of high in and and classification of blood pressure Prevalence of hypertension data on the of hypertension and the of in different European the of hypertension to be of the with a with to be in the across with changes in the to the of results and the of a of hypertension been is a hypertension is by the important of this of hypertension and for stroke been The and of stroke in have been by of European a in to European which a in from stroke Hypertension and total cardiovascular risk a hypertension guidelines on as the or the need the the and European Society recommendations on of heart disease in and that of be to of total (or approach is now and been the 2003 and 2007 ESH/ESC guidelines for the management of arterial hypertension [1,2]. The is on the that a of the hypertensive an of with the risk when and other risk factors to a total risk that is the of in high-risk antihypertensive treatment strategies and of of drug and as as other be different from to be in is evidence in high-risk control is and the combination of antihypertensive drugs with other as The therapeutic approach total risk in to in to of the management of Assessment of total cardiovascular risk of total risk is in of as with of cardiovascular disease or with elevated risk of the total risk is high or for a of patients with hypertension not to of the and the of at high or high risk the of to total risk, as to be to the therapeutic approach have been for total risk and limitations have been The been on European The the risk of from disease over years on total and The of the for which been done for European the two of one for high-risk and one for The of as Heart is to for the of on total The and their in risk assessment and management but be in the of the knowledge and with to the that total risk is associated with when with other strategies not been be in the subjects and with the risk associated with is in subjects in individuals and from with elevated an not the diagnostic for with and with a history of the of years in and years in total risk is as the risk of from of on in total risk be in the of high with risk this to a high-risk years treatment be by of risk or by heart and is in the European on in Clinical which is when been to of asymptomatic in in the which the risk that by the of risk is to for asymptomatic evidence for the risk of is a guidelines for the management of hypertension and 2003 Society of Hypertension Guidelines and the 2003 and 2007 ESH/ESC have risk in different on risk asymptomatic and of or chronic kidney disease as done by the ESC guidelines The classification in high and high risk is in the guidelines and to the risk of as by the ESC guidelines The factors on which the is in Table of total risk in of high and high risk according to and and of asymptomatic stage or with a high normal but a out-of-office have a risk in the hypertension with a high but normal out-of-office is or have risk hypertension for the for of total risk in Limitations for risk assessment have limitations that be The of in of risk is on the damage is on limitations be that the of total risk is to the of to that to grade in to the of risk is by or to a which treatment is be in that to high total risk is as as the of a value to this and at is a of on total risk is that adults to high-risk when have one major risk and a in many elderly a high total risk level at risk to their The consequences that in is and is to subjects at high risk the in the of their to an risk to a high and risk in with of their Summary of recommendations on total cardiovascular risk assessment cardiovascular risk The evaluation of a with hypertension (i) the diagnosis of (ii) of secondary and (iii) risk, and for measurement, history history, physical laboratory investigations and diagnostic of the investigations in in Bood pressure measurement Office or clinic blood pressure be a in not or be according to and their be in a laboratory of at the is and and be to the the of a and which been to an risk the with the be is by one a with measurement, it be to elderly patients and in other conditions in which be or it is that be 1 and 3 after of the as a reduction in of or in of 3 of been to a for and of in the with the in an isolated providing information be as a to and to by or be associated with measurement of heart heart or in hypertension for in Table Office blood pressure Out-of-office blood pressure The major of out-of-office is that it a of from the which a assessment of Out-of-office is by or by principles and for the two of in to recommendations for measurement The be to the with and in of appropriate of the results that the of out-of-office is for and but for the and for and and different information on the and risk and the two be regarded as or The with and is to Office is ambulatory and home and the as for the of hypertension for home and ambulatory according to the on in Table have been and according to and be properly and at 6 The be on of hypertension by and out-of-office blood pressure blood pressure aspects of aspects have been by the on Blood is with the a on the for a period, that it information on during and at during the of of the the the and from measurement by the not be the of a the be and The is to in normal but to from exercise at the of to and and the with the at heart The is to information in a on and that in to the of drug and and from at during the and be the of be that be at the during the and The to a and a of be of during and be or the be The of and the of have been to is not and be is that not be when the is and blood pressure to the and the in and be from the on the of the of and to is to in which the and from to for been that from to and from to 6 with the and but other have been as from to and from 1 to 6 the of different measurement during the and the and to for it is that be for the or to the of the to of The the and during the as the of a normal in a it is that the of a of of be as an to subjects as have been of and in that the of the is for of sleep sleep high in chronic kidney disease and of be from blood pressure and the ambulatory arterial stiffness their value is not and be regarded as with of in in and guidelines information on for in which the need for a an a to compare and a a of as of ambulatory studies have that hypertensive ventricular hypertrophy and other of with ambulatory with been to have a with or studies in which a value to ambulatory Evidence from of published observational studies and data that ambulatory in is a risk of as or and The of ambulatory been in the in and in and in and hypertensive in patients at high risk and in patients with or renal disease that for and in the that is a The is a of but information over and to the the is that the of is in patients with a in in with the of this the of the results for in have an risk for stroke data on the risk in and the of this is blood pressure aspects The on Blood a of recommendations for The of in some the of a or be on the not but their be in subjects with an diagnostic be on at and on in the as as in the is in a with the in the and after of and with two the results in a after by the not be which be by in a is the of with of the of and for be of of the results be the of the When with over or in the with ambulatory it over and is and it not data during and during or the of of home is to and of the studies in the in care and in hypertensive that the of and is with home with in which both and that home is at as with as is the ambulatory and that the of home is to that of ambulatory after for and White-coat (or isolated office) hypertension and masked (or isolated ambulatory) hypertension Office is of the which been to the a to the and in which to the a factors in or out-of-office be the the two is the or or clinic to the in which is elevated in the at visits and normal of the on or be normal in the and high of the which is or ambulatory The or and when both of measurement normal or the value for is the studies in white-coat or masked hypertension have a value of for out-of-office or home and for is the of white-coat or masked hypertension by or is that the and be to White-coat hypertension on the of white-coat hypertension and it to hypertensive subjects in to of white-coat hypertension and Prevalence is in the of target or when is on or when by a or The is to the level of for the of white-coat hypertension to in grade 1 hypertension and to in grade 3 hypertension is in white-coat hypertension in hypertension and studies have this to be the for subjects with white-coat hypertension be to individuals is an because, in some the risk of this was to be hypertension and in it was not different from when for and other The white-coat hypertensive patients the reduction of clinic to a reduced of Other factors to with in white-coat hypertensive (i) out-of-office is (ii) asymptomatic as be and (iii) this is the for metabolic risk factors and risk of diabetes and to hypertension is that the diagnosis of white-coat hypertension be and patients be and out-of-office Masked hypertension The of masked hypertension in studies factors out-of-office to as alcohol physical and history of hypertension and the is when is in the high normal Masked hypertension is associated with other risk asymptomatic and risk of diabetes and hypertension of studies that the of is two in and is to the in The that masked hypertension is and have to this patients masked hypertension is associated with an risk of when the during the Clinical indications for out-of-office blood pressure is now that out-of-office is an important to measurement, but the the for diagnosis and management of The value of to be important which have to the that out-of-office an important role in hypertension important and the choice the two in the on of assessment of the be in care and in it is to or on with which is the for out-of-office with the of providing not be with of in to for which is not be of or physical or be of or in which be as indications for out-of-office measurement for diagnostic in Table Clinical indications for out-of-office blood pressure measurement for diagnostic Blood pressure during exercise and laboratory stress during and the is for systolic for on a or a be with is on the normal during exercise of for and women been in a of but other of an to exercise have been the of at exercise is to arterial stiffness and and is in women in and in in individuals not have that an of during exercise the of hypertension in of at exercise to future hypertension is not of a of as of of and is on the of exercise with as after for and other as in as in hypertensive patients the results on the of exercise not which be to the that the two of in during is that the is a reduction of during with changes in and or not the arterial is an of at on subjects and in hypertensive patients with of an a the of normal hypertension be an for of with masked hypertension the other when hypertension is associated with dysfunction and of the of exercise be a during exercise a as in individuals in patients with disease or with heart failure in a exercise systolic the results the of during exercise for diagnostic and in patients with exercise is as a exercise and data and an of stress have been to stress and a of or laboratory stress in not stress and not have and to the results on the of the to with future hypertension not the is that to stress an on future risk of elevated ventricular atherosclerosis and The results that during stress not Central blood pressure The measurement of in hypertensive patients of both value for and the of antihypertensive with The arterial pressure is a of the pressure by ventricular and a be at the in the it the on kidney and The of be the as the the and systolic as a of the for heart to the of and pressure the arterial systolic and be different from the years and have been to systolic or pressure from pressure have been in an document studies in the that and by of and in patients with in the value of was or not in studies the guidelines, previous the measurement of and is of for in and is their The be in the in some of individuals at the level be to high of the pressure is normal Medical history The history the of the diagnosis of arterial and and and antihypertensive be to indications of secondary of Women be Hypertension an risk of renal and heart when a history of be in to assessment of risk, as or a history of heart or heart disease, with an on stroke and transient ischaemic attack history of the and of kidney and evidence for be history of hypertension is an important of to hypertension and and on and history in Table and Physical examination Physical examination to or the diagnosis of for secondary of hypertension and risk be as in and be to the diagnosis of at one to be at both and the two in in investigations of patients of the heart and renal renal on the of the and be with the and and heart be the is at heart an risk of heart the of on physical examination in Table Physical examination for secondary organ damage and Summary of recommendations on blood pressure history, and physical examination pressure history, and physical on Blood pressure history, and physical Laboratory investigations Laboratory investigations at providing evidence for the of risk for secondary hypertension and for the or of from the to the on laboratory investigations in Table Laboratory Genetics history is a in hypertensive patients with the to and in the of studies and been for ambulatory forms of hypertension have been as syndrome and a the of hypertension and the treatment hypertension is a with a studies and their to a total of which associated with systolic to risk for Searching for asymptomatic organ damage to the of asymptomatic as an stage in the of disease, and as a of risk, of organ be by appropriate be that a of evidence is now on the role of asymptomatic in the risk of individuals with and high The that of of and of is a in of assessment of in data from studies in different be is that the risk as the of Heart be of the assessment of hypertensive in is by the the or been in observational studies and trials to be an of the is at in patients over years of be to of ventricular or which risk and is when and ischaemic Atrial fibrillation is a and of in hypertensive patients of fibrillation the of by appropriate therapy not from is in and is to and renal risk in a of risk and in therapy evaluation of the in hypertensive patients of and and While ventricular for or the or of is according to the Society of the and risk is of for women and for for of of for in which to the of or been be in and patients in to to and of been that the is to by to the and that different for and women be by in subjects and in with with and with normal an of but is the of risk Hypertension is associated with of and as dysfunction is associated with and of heart when is normal failure with The and heart failure and but is not to the hypertensive and to recommendations it be with of the of the is of hypertensive heart disease the is reduced the and of dysfunction is on of and and the and and is an important of in a The of and of on and on The is to an of The value of is in the hypertensive and is associated with risk, of and in hypertensive patients of information and is a for the diagnosis of Left is by or been to be an of heart fibrillation and ischaemic stroke and for hypertensive heart disease for in Table The for in hypertension is to by that the on of and from control with the for by the Society of and the European of in the of for from in different be for in the assessment of and in patients with on and systolic and to systolic dysfunction of hypertensive patients assessment of systolic in hypertensive heart disease not information to at in the of a normal be in hypertensive patients in different and with different in hypertensive patients at total risk, it the risk evaluation by by in hypertensive patients with evidence of it the hypertrophy and and in hypertensive patients with it to is that assessment of and be of diagnostic value in patients with hypertension and be in hypertensive patients at the a or on and be for assessment of and when is not and when of have therapeutic consequences for diagnosis of in hypertensive patients with is hypertension the of exercise and exercise a normal and an value in patients of When the exercise is or an of as stress or stress is for a of for artery with normal associated with disease The of of and on the artery been to from isolated damage been to have an value in hypertension Blood vessels Carotid examination of the with measurement of the of been to the of both stroke and of risk factors both for the value at the and for the value at the level of the artery The and is a one and a for high risk is a been as a of in the 2007 Guidelines the value for high risk was in the elderly patients of the and in the patients of the European on and of a be identified by an or by a in of or of the value a value for of a and to other for and patients risk in the review that the value of be in asymptomatic individuals at

  1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement2009
  2. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The JNC 7 Report2003
  3. The National Comprehensive Cancer Network1998
  4. Standardisation of spirometry2005
  5. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science2009

Metadata from OpenAlex (CC0). Citations are generated from the published record.